[go: up one dir, main page]

SV2003001098A - Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion - Google Patents

Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion

Info

Publication number
SV2003001098A
SV2003001098A SV2002001098A SV2002001098A SV2003001098A SV 2003001098 A SV2003001098 A SV 2003001098A SV 2002001098 A SV2002001098 A SV 2002001098A SV 2002001098 A SV2002001098 A SV 2002001098A SV 2003001098 A SV2003001098 A SV 2003001098A
Authority
SV
El Salvador
Prior art keywords
procedure
preparation
pharmaceutical formulation
flavor
masked flavor
Prior art date
Application number
SV2002001098A
Other languages
English (en)
Inventor
Philippe Becourt
Josiane Chauvin
Detlev Schwabe
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of SV2003001098A publication Critical patent/SV2003001098A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A UNA FORMULACION FARMACEUTICA EN FORMA DE POLVO, DESTINADA A SER ADMINISTRADA EN SUSPENSION ACUOSA POR VIA ORAL, QUE TIENE EL SABOR ENMASCRADO, QUE ICNLUYE POR LO MENOS UN POLIMERO CELULOSICO, UN POLIMERO METACRILICO Y UN PRINCIPIO ACTIVO DISTRIBUIDO DE MANERA HOMOGENEA Y EN ESTADO MOLECULAR EN UNA MATRIZ ATOMIZADA, ASI COMO UN AGENTE ALCALINO Y UN AGENTE ABSORBENTE, EL PROCEDIMIENTO PRA SU PREPARACION, ASI COMO A UN METODO DE ENMASCARAMIENTO DEL SABOR DE PRODUCTOS FARMACEUTICOS.
SV2002001098A 2001-06-21 2002-06-19 Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion SV2003001098A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0108157A FR2826274B1 (fr) 2001-06-21 2001-06-21 Formulation pharmaceutique au gout masque et son procede de preparation

Publications (1)

Publication Number Publication Date
SV2003001098A true SV2003001098A (es) 2003-03-18

Family

ID=8864587

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002001098A SV2003001098A (es) 2001-06-21 2002-06-19 Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion

Country Status (41)

Country Link
US (2) US7138138B2 (es)
EP (1) EP1401397B1 (es)
JP (1) JP4880871B2 (es)
CN (1) CN1239149C (es)
AP (1) AP1595A (es)
AR (1) AR036096A1 (es)
AT (1) ATE290366T1 (es)
AU (1) AU2002329311B2 (es)
BG (1) BG66314B1 (es)
BR (1) BRPI0208998A2 (es)
CA (1) CA2452239C (es)
CO (1) CO5540278A2 (es)
CZ (1) CZ299947B6 (es)
DE (1) DE60203178T2 (es)
EA (1) EA006016B1 (es)
EC (1) ECSP034915A (es)
ES (1) ES2236574T3 (es)
FR (1) FR2826274B1 (es)
GT (2) GT200200115AA (es)
HR (1) HRP20031067B1 (es)
HU (1) HUP0400799A3 (es)
IL (2) IL159404A0 (es)
JO (1) JO2325B1 (es)
MA (1) MA27042A1 (es)
MX (1) MXPA03011756A (es)
MY (1) MY134340A (es)
NO (1) NO332258B1 (es)
NZ (1) NZ530042A (es)
OA (1) OA12635A (es)
PA (1) PA8548301A1 (es)
PE (1) PE20030201A1 (es)
PL (1) PL202090B1 (es)
PT (1) PT1401397E (es)
SK (1) SK285865B6 (es)
SV (1) SV2003001098A (es)
TN (1) TNSN03141A1 (es)
TW (1) TWI228049B (es)
UA (1) UA77960C2 (es)
UY (1) UY27341A1 (es)
WO (1) WO2003000225A2 (es)
ZA (1) ZA200309479B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
GB2419094A (en) * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
FR2882522B1 (fr) 2005-02-25 2007-04-13 Aventis Pharma Sa Composition pharmaceutique solide comprenant de la telithromycine
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US20060264386A1 (en) * 2005-05-17 2006-11-23 Rongqi Sun Pharmaceutical formulations of 6-11 bicyclic ketolide derivatives and related macrolides and methods for preparation thereof
JP2009525300A (ja) * 2006-02-03 2009-07-09 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 水難溶性のポリマー及び活性薬剤の混合物を含む医薬組成物
US20100226979A1 (en) * 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
KR100935893B1 (ko) * 2007-09-11 2010-01-07 국방과학연구소 1,1'-다이메틸-5,5’-바이테트라졸의 합성방법
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
JP5597204B2 (ja) 2008-12-16 2014-10-01 カールスベア アー／エス 気相グラフティングによってヒドロキシル化された表面のコーティング
SG11201405895UA (en) 2012-03-27 2014-10-30 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
DE102012014848A1 (de) * 2012-07-27 2012-10-31 Heilerde-Gesellschaft Luvos Just GmbH & Co. KG Heilerde-Zubereitung
RU2017104163A (ru) * 2014-08-05 2018-09-06 Семпра Фармасьютикалз, Инк. Порошкообразные составы пероральных суспензий антибактериальных агентов
US10982177B2 (en) 2017-09-18 2021-04-20 The Clorox Company Cleaning wipes with particular lotion retention and efficacy characteristics
CN114209661B (zh) * 2022-02-21 2022-04-29 北京罗诺强施医药技术研发中心有限公司 呈细粒形式的固体药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930409A1 (de) * 1979-07-26 1981-02-12 Bayer Ag Spruehtrocknung von mikrokapseldispersionen
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
AU9182498A (en) * 1997-10-03 1999-04-27 Elan Corporation, Plc Taste masked formulations
IN191239B (es) * 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
ATE408614T1 (de) * 2000-08-22 2008-10-15 Basilea Pharmaceutica Ag Neue macrolide mit antibakterieller wirkung

Also Published As

Publication number Publication date
FR2826274B1 (fr) 2003-09-26
IL159404A0 (en) 2004-06-01
BG108458A (bg) 2005-02-28
GT200200115AA (es) 2005-01-12
MA27042A1 (fr) 2004-12-20
NO332258B1 (no) 2012-08-13
PL366803A1 (en) 2005-02-07
JP4880871B2 (ja) 2012-02-22
TWI228049B (en) 2005-02-21
US20070014857A1 (en) 2007-01-18
JO2325B1 (en) 2006-06-28
SK285865B6 (sk) 2007-10-04
HUP0400799A2 (hu) 2004-08-30
FR2826274A1 (fr) 2002-12-27
WO2003000225A2 (fr) 2003-01-03
NZ530042A (en) 2005-09-30
WO2003000225A3 (fr) 2003-03-13
AP2003002927A0 (en) 2003-12-31
ES2236574T3 (es) 2005-07-16
DE60203178D1 (de) 2005-04-14
EP1401397A2 (fr) 2004-03-31
UA77960C2 (en) 2007-02-15
ECSP034915A (es) 2004-02-26
EA200400061A1 (ru) 2004-06-24
CA2452239C (fr) 2011-07-19
GT200200115A (es) 2003-02-27
US7138138B2 (en) 2006-11-21
DE60203178T2 (de) 2006-01-26
PE20030201A1 (es) 2003-03-12
CZ299947B6 (cs) 2009-01-07
UY27341A1 (es) 2003-01-31
JP2004534810A (ja) 2004-11-18
PL202090B1 (pl) 2009-06-30
ZA200309479B (en) 2005-04-26
HK1067558A1 (en) 2005-04-15
BRPI0208998A2 (pt) 2017-06-06
CO5540278A2 (es) 2005-07-29
CA2452239A1 (fr) 2003-01-03
HUP0400799A3 (en) 2012-08-28
EP1401397B1 (fr) 2005-03-09
PA8548301A1 (es) 2003-09-05
NO20035581D0 (no) 2003-12-15
CN1529585A (zh) 2004-09-15
HRP20031067A2 (en) 2004-04-30
HRP20031067B1 (en) 2011-10-31
MXPA03011756A (es) 2004-07-01
MY134340A (en) 2007-12-31
BG66314B1 (bg) 2013-04-30
ATE290366T1 (de) 2005-03-15
CN1239149C (zh) 2006-02-01
AU2002329311B2 (en) 2007-02-01
AP1595A (en) 2006-04-12
OA12635A (fr) 2006-06-15
TNSN03141A1 (fr) 2005-12-23
PT1401397E (pt) 2005-05-31
IL159404A (en) 2007-08-19
US20040142029A1 (en) 2004-07-22
EA006016B1 (ru) 2005-08-25
CZ20033441A3 (en) 2004-03-17
SK15922003A3 (sk) 2004-05-04
AR036096A1 (es) 2004-08-11

Similar Documents

Publication Publication Date Title
SV2003001098A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
BR0112495A (pt) Forma de dosagem, processo para a produção de uma forma de dosagem e uso da forma de dosagem
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
MXPA05007643A (es) Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo.
WO2005009357A3 (en) Controlled release compositions
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
NO20075136L (no) Nye liposompreparater
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
CL2004000931A1 (es) Pelicula consumible adaptada para adherirse y disolverse en la cavidad bucal que comprende un almidon modificado y un agente farmaceuticamente activo.
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
BR0306501A (pt) Método para uso e produção de um tampão com medicamento
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
DE60140997D1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung
PE20050443A1 (es) Formulaciones farmaceuticas transdermicas
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
AR047480A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina

Legal Events

Date Code Title Description
FG Grant
FD Lapse